Cytognomix Inc. offers software that accelerates determination of radiation exposure
LONDON, ON, Aug. 24, 2017 /CNW/ - The Government of Canada is committed to growing the economy, strengthening the middle class, and helping those working hard to join it. Through the Build in Canada Innovation Program, the Government of Canada is investing in Canadian innovations to create inclusive and sustainable economic growth for communities across Canada.
Peter Fragiskatos, Member of Parliament for London North Centre, today announced that the Government of Canada is investing in new technology to accelerate determination of radiation exposure level by genetic analysis.
Cytognomix Inc. of London, Ontario, received a $263,713 contract for its Automated Dicentric Chromosome Identifier (ADCI) software system. The innovation collects and analyzes multiple digital images of cells containing chromosomes exposed to radiation. The software can process images faster and more accurately than similar products to generate new data on the behaviour of those cells and chromosomes. The ADCI software system is currently being tested by Health Canada.
This investment was made through the Build in Canada Innovation Program, which helps Canadian innovators land their first sale and get their innovations tested by the Government of Canada. This program is just one of the many ways the Government of Canada supports innovation and small and medium-sized businesses across Canada.
Canadian innovators can submit their proposals on the Build in Canada Innovation Program's website.
Quotes
"Our country is full of companies like Cytognomix Inc. that are helping Canada become a leader in innovative technology. By matching innovative products with government needs, the Build in Canada Innovation Program helps Canadian companies move their products from the lab to the marketplace, enabling these companies to grow while providing good middle-class jobs."
Steven MacKinnon
Parliamentary Secretary to the Minister of Public Services and Procurement
"The government's investments in Ontario businesses such as Cytognomix Inc. are creating economic opportunities and good quality jobs for the middle class in our communities. Through its research, Cytognomix Inc. helps improve Canadians' lives, health and well-being."
Peter Fragiskatos
Member of Parliament for London North Centre
"The Build in Canada Innovation Program has provided an opportunity for Cytognomix Inc. to test its software with Health Canada and further improve the product. This innovation will be beneficial in aiding our response to radiological and nuclear emergencies."
Ruth Wilkins
Research Scientist, Head Radiobiology Unit
Health Canada
"The Build in Canada Innovation Program has provided critical support and impetus for us to get our product market-ready for our government testing partners and other customers. It bridges an important unmet need that is not served by any other federal or provincial program."
Dr. Peter K. Rogan
President of Cytognomix Inc.
Quick facts
- Established in 2009, Cytognomix Inc. is a biotechnology company that designs and markets advanced genomic reagents and software-based solutions. Its products personalize the diagnosis, evaluation and management of cancer, prenatal disorders and other genetic diseases.
- The ADCI software system selects high-quality cells from all types of commercial images for analysis, identifies chromosome anomalies, builds biodosimetry calibration curves and estimates exposure in less than an hour.
- More than 245 contracts have been awarded under the Build in Canada Innovation Program, bringing Canadian companies one step closer to selling to domestic and international markets.
- More than $105 million has been awarded in contracts since the Build in Canada Innovation Program began in 2010.
Associated links
Build in Canada Innovation Program
Follow us on Twitter
Follow us on Facebook
SOURCE Public Services and Procurement Canada
Mary-Rose Brown, Office of the Honourable Judy M. Foote, 819-997-5421; Media Relations, Public Services and Procurement Canada, 819-420-5501, [email protected]
Share this article